Who are Xolair Prefilled Syringe's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xolair-prefilled-syringe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Xolair Prefilled Syringe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xolair Prefilled Syringe (Xolair Prefilled Syringe) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-IgE). Area: Immunology / Allergy.

phase 3 Monoclonal antibody (anti-IgE) Immunoglobulin E (IgE) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Xolair Prefilled Syringe (Xolair Prefilled Syringe) — Kashiv BioSciences, LLC. Xolair (omalizumab) is a monoclonal antibody that binds to circulating immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xolair Prefilled Syringe TARGET	Xolair Prefilled Syringe	Kashiv BioSciences, LLC	phase 3	Monoclonal antibody (anti-IgE)	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-IgE) class)

Kashiv BioSciences, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xolair Prefilled Syringe — Competitive Intelligence Brief. https://druglandscape.com/ci/xolair-prefilled-syringe. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab